AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for THOMAS E. PEREZ
-0.04 (-0.19%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.48 - 21.74
52 week 20.48 - 77.73
Open 21.55
Vol / Avg. 1.26M/1.05M
Mkt cap 724.75M
P/E 4.60
Div/yield     -
EPS 4.66
Shares 34.70M
Beta 0.85
Inst. own 116%
Feb 24, 2016
AMAG Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference - 8:30AM EST - Add to calendar
Feb 17, 2016
Q4 2015 AMAG Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 17, 2016
Q4 2015 AMAG Pharmaceuticals Inc Earnings Call - 8:00AM EST - Add to calendar
Feb 10, 2016
AMAG Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Jan 13, 2016
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 13, 2016
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Jan 11, 2016
Preliminary Q4 2015 AMAG Pharmaceuticals Inc Earnings Release
Nov 18, 2015
AMAG Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -21.41% 109.19%
Operating margin -12.31% -3.08%
EBITD margin - 11.78%
Return on average assets -3.94% 16.42%
Return on average equity -10.11% 42.96%
Employees 257 -
CDP Score - -


1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Officers and directors

Gino Santini Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Frank E. Thomas President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Nicholas Grund Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Nathan McBride Senior Vice President - Innovation Architects and Chief Information Officer
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Todd H. Van Horn General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG
Bio & Compensation  - Reuters
Elizabeth Bolgiano Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Robert M. Brenner M.D. Senior Vice President - Medical Affairs
Age: 45
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development & Strategy
Bio & Compensation  - Reuters